Li Xiaowang, Fang Fei
Cardiovascular Interventional Treatment Center, First Affiliated Hospital of Huzhou University, Huzhou First People's Hospital, Huzhou, 313000, Zhejiang, China.
Geriatrics Department, Huzhou Third Municipal Hospital, The Affiliated Hospital of Huzhou University, 2088 Tiaoxi East Road, Wuxing District, Huzhou, 313000, Zhejiang, China.
Eur Geriatr Med. 2025 Feb;16(1):165-177. doi: 10.1007/s41999-024-01112-9. Epub 2024 Dec 4.
To synthesize evidence, using data from published studies, on the association of frailty with the outcomes after cardiac resynchronization therapy (CRT).
The systematic search of PubMed, Web of Science, Scopus, and Embase databases was done to identify observational studies (cohort/case-control/cross-sectional) that used an objective method for frailty assessment and had presented adjusted effect sizes. STATA version 15.0 was used to conduct analysis, which was based on random effects model.
Fifteen studies were included. Frailty was found to be associated with an increased risk of in-hospital mortality (odds ratio (OR) 6.96, 95% confidence interval (CI) 5.48, 8.85). The effect of frailty on the response to CRT was not statistically significant (OR 0.55, 95% CI 0.19, 1.59). The pooled effect size indicated that frailty was associated with somewhat bigger but not statistically significant increase in the risk of complications (OR 1.70, 95% CI 0.93, 3.12). The risks of mortality and decompensated heart failure on long-term follow up were higher in frail patients (Hazard ratio (HR) 1.75, 95% CI 1.40, 2.17 and HR 3.03, 95% CI 1.33, 6.90, respectively) compared to patients without frailty. The risk of readmission was higher in frail patients, however, it did not achieve statistical significance (HR 2.63, 95% CI 0.89, 7.75).
Frail CRT patients could be at higher risks of mortality, decompensated heart failure, and may have potentially higher rates of complications. Integrating frailty assessment into pre-CRT evaluation and customizing interventions for frail patients might be an essential steps towards enhancing outcomes in this population.
利用已发表研究的数据,综合分析衰弱与心脏再同步治疗(CRT)后结局之间的关联。
系统检索PubMed、Web of Science、Scopus和Embase数据库,以确定使用客观方法评估衰弱且呈现调整后效应量的观察性研究(队列研究/病例对照研究/横断面研究)。使用STATA 15.0版本进行基于随机效应模型的分析。
纳入15项研究。发现衰弱与住院死亡率增加相关(优势比(OR)6.96,95%置信区间(CI)5.48,8.85)。衰弱对CRT反应的影响无统计学意义(OR 0.55,95% CI 0.19,1.59)。合并效应量表明,衰弱与并发症风险的增加幅度稍大但无统计学意义相关(OR 1.70,95% CI 0.93,3.12)。与非衰弱患者相比,衰弱患者长期随访时的死亡风险和失代偿性心力衰竭风险更高(风险比(HR)分别为1.75,95% CI 1.40,2.17和HR 3.03,95% CI 1.33,6.90)。衰弱患者再次入院的风险更高,然而未达到统计学意义(HR 2.63,95% CI 0.89,7.75)。
CRT衰弱患者可能有更高的死亡、失代偿性心力衰竭风险,且可能有更高的并发症发生率。将衰弱评估纳入CRT前评估并为衰弱患者定制干预措施可能是改善该人群结局的重要步骤。